Fulvestrant (FASLODEXâ„¢) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Breast Cancer
DRUG: Fulvestrant
Anti-proliferative effect after 4 weeks of treatment.
Safety, tolerability, tumor response and pharmacokinetics after 4 weeks of treatment.
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.